Association between Vaccination for Herpes Zoster and Risk of Herpes Zoster Infection among Older Patients with Selected Immune-Mediated Diseases

JAMA

Volumn 308, Issue 1, 2012, Pages 43-49

  Zhang, Jie ^a   Xie, Fenglong ^b   Delzell, Elizabeth ^a   Chen, Lang ^b   Winthrop, Kevin L ^d   Lewis, James D ^e   Saag, Kenneth G ^b   Baddley, John W ^c,f   Curtis, Jeffrey R ^a,b  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^b The University of Alabama at Birmingham   (United States)

^c University of Alabama at Birmingham   (United States)

^d OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^e UNIVERSITY OF PENNSYLVANIA   (United States)

^f BIRMINGHAM VA MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABATACEPT; ADALIMUMAB; AZATHIOPRINE; CYCLOSPORIN; ETANERCEPT; GLUCOCORTICOID; HERPES VACCINE; HYDROXYCHLOROQUINE; INFLIXIMAB; LEFLUNOMIDE; MERCAPTOPURINE; METHOTREXATE; RITUXIMAB; SALAZOSULFAPYRIDINE; LIVE VACCINE; VARICELLA ZOSTER VACCINE;

ADULT; AGED; AGING; ANKYLOSING SPONDYLITIS; ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE ASSOCIATION; DRUG EFFICACY; DRUG SAFETY; ENTERITIS; FEMALE; HERPES ZOSTER; HUMAN; INCIDENCE; INFECTION RISK; MAJOR CLINICAL STUDY; MALE; MEDICARE; PRIORITY JOURNAL; PSORIASIS; PSORIATIC ARTHRITIS; RETROSPECTIVE STUDY; RHEUMATOID ARTHRITIS; SENSITIVITY ANALYSIS; SEX DIFFERENCE; TREATMENT DURATION; VACCINATION; AUTOIMMUNE DISEASE; DRUG CONTRAINDICATION; IMMUNOLOGY; MIDDLE AGED; UNITED STATES;

AGED; AGED, 80 AND OVER; AUTOIMMUNE DISEASES; COHORT STUDIES; FEMALE; HERPES ZOSTER; HERPES ZOSTER VACCINE; HUMANS; INCIDENCE; MALE; MEDICARE; MIDDLE AGED; RETROSPECTIVE STUDIES; UNITED STATES; VACCINES, ATTENUATED;

EID: 84863515640     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.2012.7304     Document Type: Article

References (23)

1. Mueller NH, Gilden DH, Cohrs RJ, Mahalingam R, Nagel MA. Varicella zoster virus infection: clinical features, molecular pathogenesis of disease, and latency. Neurol Clin. 2008;26(3):675-697. (Pubitemid 352020491)
2. Insinga RP, Itzler RF, Pellissier JM, Saddier P, Nikas AA. The incidence of herpes zoster in a United States administrative database. J Gen Intern Med. 2005;20(8):748-753. (Pubitemid 41141008)
3. Schmader KE, Levin MJ, Gnann JW Jr, et al. Efficacy, safety, and tolerability of herpes zoster vaccine in persons aged 50-59 years. Clin Infect Dis. 2012;54(7):922-928.
4. Oxman MN, Levin MJ, Johnson GR, et al Shingles Prevention Study Group. A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. N Engl J Med. 2005;352(22):2271-2284.
5. Advisory Committee on Immunization Practices. Recommended adult immunization schedule: United States, 2011. Ann Intern Med. 2011;154(3):168-173.
6. Strangfeld A, Listing J, Herzer P, et al. Risk of herpes zoster in patients with rheumatoid arthritis treated with anti-TNF-α agents. JAMA. 2009;301(7):737-744.
7. Gupta G, Lautenbach E, Lewis JD. Incidence and risk factors for herpes zoster among patients with inflammatory bowel disease. Clin Gastroenterol Hepatol. 2006;4(12):1483-1490. (Pubitemid 44880029)
8. Smitten AL, Choi HK, Hochberg MC, et al. The risk of herpes zoster in patients with rheumatoid arthritis in the United States and the United Kingdom. Arthritis Rheum. 2007;57(8):1431-1438. (Pubitemid 350308841)
9. Marehbian J, Arrighi HM, Hass S, Tian H, Sandborn WJ. Adverse events associated with common therapy regimens for moderate-to-severe Crohn's disease. Am J Gastroenterol. 2009;104(10):2524-2533.
10. Wolfe F, Michaud K, Chakravarty EF. Rates and predictors of herpes zoster in patients with rheumatoid arthritis and non-inflammatory musculoskeletal disorders. Rheumatology (Oxford). 2006;45(11):1370-1375. (Pubitemid 44605471)
11. Harpaz R, Ortega-Sanchez IR, Seward JF; Advisory Committee on Immunization Practices (ACIP) Centers for Disease Control and Prevention (CDC). Prevention of herpes zoster: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2008;57(RR-5):1-30.
12. Singh JA, Furst DE, Bharat A, et al. 2012 update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis. Arthritis Care Res (Hoboken). 2012;64(5):625-639.
13. Nelson KE, Williams CM, Graham NMH. Infectious Disease Epidemiology. Sudbury, MA: Jones & Bartlett Publishers; 2004.
14. Marin M, Güris D, Chaves SS, Schmid S, Seward JF; Advisory Committee on Immunization Practices, Centers for Disease Control and Prevention (CDC). Prevention of varicella: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2007;56(RR-4): 1-40.
15. Donahue JG, Choo PW, Manson JE, Platt R. The incidence of herpes zoster. Arch Intern Med. 1995;155(15):1605-1609.
16. Yawn BP, Wollan P, St Sauver J. Comparing shingles incidence and complication rates from medical record review and administrative database estimates: how close are they? Am J Epidemiol. 2011;174(9):1054-1061.
17. Hanley JA, Lippman-Hand A. If nothing goes wrong, is everything all right? interpreting zero numerators. JAMA. 1983;249(13):1743-1745.
18. Tseng HF, Smith N, Harpaz R, Bialek SR, Sy LS, Jacobsen SJ. Herpes zoster vaccine in older adults and the risk of subsequent herpes zoster disease. JAMA. 2011;305(2):160-166.
19. Zhang J, Delzell ES, Xie F, et al. The use, safety, and effectiveness of herpes zoster vaccination in individuals with inflammatory and autoimmune diseases: a longitudinal observational study. Arthritis Res Ther. 2011;13(5):R174.
20. Scheinberg M, Guedes-Barbosa LS, Mangueira C, et al. Yellow fever revaccination during infliximab therapy. Arthritis Care Res (Hoboken). 2010;62 (6):896-898.
21. Kilgore PE, Kruszon-Moran D, Seward JF, et al. Varicella in Americans from NHANES III: implications for control through routine immunization. J Med Virol. 2003;70(suppl 1):S111-S118. (Pubitemid 36368856)
22. Gershon AA, Levin MJ, Weinberg A, et al Pediatric AIDS Clinical Trials Group 391 Team. A phase I-II study of live attenuated varicella-zoster virus vaccine to boost immunity in human immunodeficiency virus-infected children with previous varicella. Pediatr Infect Dis J. 2009;28(7):653-655.
23. Son M, Shapiro ED, LaRussa P, et al. Effectiveness of varicella vaccine in children infected with HIV. J Infect Dis. 2010;201(12):1806-1810.